biohaven pharmaceuticals Logo (WIPO, 14.12.2021)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke biohaven pharmaceuticals wurde als Bildmarke am 14.12.2021 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Andere Polygone #Briefe, die eine besondere Form des Schreibens darstellen #Mehrere Polygone, nebeneinander liegend, verbunden oder sich überschneidend #Briefe, die von einem Zeichen unverhältnismäßiger Größe überragt werden #Serie von Briefen, die verschiedene Formen des Schreibens darstellen #Buchstabenreihen in verschiedenen Dimensionen
| Markenform | Bildmarke |
| Aktenzeichen | 1650146 |
| Länder | 
|
| Basismarke |
Nr. 90788388,
22. Juni 2021
|
| Anmeldedatum | 14. Dezember 2021 |
| Ablaufdatum | 14. Dezember 2031 |
Markeninhaber
Ritter House, P.O. Box 173,
Road Town
VG
Road Town
VG
Markenvertreter
1100 NEW YORK AVENUE, N.W.
WASHINGTON DC 20005
US
Waren und Dienstleistungen
05
Medicated and pharmaceutical preparations, both prescription
and over-the-counter, for use in connection with humans and
animals, namely, for the treatment of central nervous system
disorders, neurologic illnesses, and psychiatric illnesses;
pharmaceutical preparations for the treatment of brain
ischemia; pharmaceutical preparations for the treatment of
brain ischemia, namely, post-stroke recovery, severe
intracranial atherosclerosis, carotid endarterectomy,
cardiac bypass, cerebral vasculitis, reversible cerebral
vasoconstriction syndrome; pharmaceutical preparations for
the treatment of brain and cord injuries; pharmaceutical
preparations for the treatment of brain and cord injuries,
namely, post- intracranial hemorrhage recovery, traumatic
brain injury, spinal cord injury; pharmaceutical
preparations for the treatment of neurodegenerative
diseases; pharmaceutical preparations for the treatment of
neurodegenerative diseases, namely, Alzheimer's disease
(AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's
disease, Lewy body dementia, frontotemporal dementia,
vascular dementia, Parkinson's disease, cognitive impairment
of aging, progressive Multiple Sclerosis; pharmaceutical
preparations for the treatment of optic and retinal
neuropathies; pharmaceutical preparations for the treatment
of optic and retinal neuropathies, namely, glaucoma,
diabetic retinopathy, ischemic optic and retinal
neuropathies; pharmaceutical preparations for the treatment
of pain; pharmaceutical preparations for the treatment of
pain, namely, opioid sparing analgesia, cancer pain, chronic
neuropathic pain, peripheral neuropathy, low back pain in
the nature of failed back surgery syndrome, radiculopathy in
the nature of sciatica, diabetic peripheral neuropathy,
post-herpetic neuralgia, chemotherapy induced neuropathy and
other medication induced neuropathies, complex regional pain
syndrome, fibromyalgia, chronic post-operative pain, cluster
thoracotomy, phantom limb, stump neuroma; pharmaceutical
preparations for the treatment of headache and facial pain,
namely, headache, migraine, chronic daily headache, cluster
headache, trigeminal neuralgia; pharmaceutical preparations
for symptomatic treatments of degenerative diseases;
pharmaceutical preparations for symptomatic treatments of
degenerative diseases, namely, breath holding in Rett
syndrome, dystonias, dysphagia, gait abnormalities, bulbar
function in Amyotrophic Lateral Sclerosis (ALS),
pseudobulbar affect, levodopa-induced dyskinesias in
Parkinson's disease, agitation in Alzheimer's disease (AD),
disinhibition in dementia; pharmaceutical preparations for
the treatment of epilepsy; pharmaceutical preparations for
the treatment of epilepsy, namely, precision medicine for
the adjuvant for genetic epilepsy due to NMDA receptor
mutations with hyperactivation; pharmaceutical preparations
for the treatment of neuropsychiatric disorders;
pharmaceutical preparations for the treatment of
neuropsychiatric disorders, namely, treatment resistant
depression, Post Traumatic Stress Disorder (PTSD) in the
nature of hyperarousal, substance abuse disorders, addiction
disorders, Obsessive Compulsive Disorder (OCD), hoarding,
trichotillomania, eating disorders, Generalized Anxiety
Disorder (GAD), adjustment disorders, panic disorder, major
depressive episode, bipolar disorder in the nature of manic
and depressive episodes, dysthymia, cyclothymia, psychotic
disorders, schizophrenia; pharmaceutical preparations for
the treatment of cerebellar disorders; pharmaceutical
preparations for the treatment of cerebellar disorders,
namely, spinocerebellar ataxia, Friedriech's ataxia,
multisystem atrophy, essential tremor; pharmaceutical
preparations for the treatment of hearing disorders,
tinnitus, delirium, sleep disorders, parasomnias, learning
disorders, Attention Deficit Disorder (ADD), Pervasive
Developmental Disorders (PDD), Asperger's syndrome, autism,
menopausal hot flashes; pharmaceutical preparations for the
treatment of cancer; pharmaceutical preparations for the
treatment of cancer, namely, monotherapy and adjunctive use
42
Pharmaceutical research and development in the fields of
headache, facial pain, impulse control disorders,
neurological disorders, and neurodegenerative disorders, and
consultation provided in conjunction therewith
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 18. Juli 2023 | 2023/29 Gaz | IS | Ablehnung |
| 11. Juli 2023 | 2023/28 Gaz | KR | Ablehnung |
| 18. April 2023 | 2023/18 Gaz | SG | Ablehnung |
| 10. März 2023 | 2023/11 Gaz | LI | Ablehnung |
| 08. März 2023 | 2023/11 Gaz | BR | Ablehnung |
| 07. März 2023 | 2023/10 Gaz | UA | Ablehnung |
| 02. März 2023 | 2023/10 Gaz | IL | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 09. Februar 2023 | 2023/6 Gaz | CH | Ablehnung |
| 30. Januar 2023 | 2023/10 Gaz | IN | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 05. Januar 2023 | 2023/1 Gaz | NZ | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 29. November 2022 | 2022/48 Gaz | CA | Ablehnung |
| 07. November 2022 | 2022/45 Gaz | MX | Ablehnung |
| 03. November 2022 | 2022/44 Gaz | JP | Ablehnung |
| 27. Oktober 2022 | 2022/43 Gaz | NO | Ablehnung |
| 20. Oktober 2022 | 2022/42 Gaz | CO | Ablehnung |
| 16. September 2022 | 2022/38 Gaz | CN | Ablehnung |
| 24. August 2022 | 2022/34 Gaz | GB | Ablehnung |
| 08. August 2022 | 2022/32 Gaz | EM | Ablehnung |
| 03. August 2022 | 2022/33 Gaz | IL | Ablehnung |
| 17. Juli 2022 | 2022/30 Gaz | NZ | Ablehnung |
| 24. Juni 2022 | 2022/27 Gaz | TR | Ablehnung |
| 06. Juni 2022 | 2022/23 Gaz | RU | Ablehnung |
| 24. Mai 2022 | 2022/21 Gaz | MC | Ablehnung |
| 05. Mai 2022 | 2022/20 Gaz | PH | Ablehnung |
| 05. April 2022 | 2022/14 Gaz | IN | Ablehnung |
| 14. Dezember 2021 | 2022/9 Gaz | US | Eintragung |
ID: 141650146